2MOV

Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal Derived AGEs.

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
2	2D 1H-1H TOCSY	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
3	3D HNCA	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
4	3D HN(CO)CA	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
5	3D CBCA(CO)NH	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
6	3D HNCO	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
7	3D 1H-13C NOESY aromatic	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
8	3D HCACO	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298
9	3D 1H-15N NOESY	0.1 mM [U-13C; U-15N] Methylglyoxal-derived hydroimidazolones isoform 1	90% H2O/10% D2O		6.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	700

NMR Refinement
Method	Details	Software
simulated annealing		XEASY

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	1000
Conformers Submitted Total Number	20
Representative Model	12 (fewest violations)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	chemical shift assignment	XEASY		Bartels et al.
2	structure solution	CYANA		Guntert, Mumenthaler and Wuthrich
3	refinement	CYANA		Guntert, Mumenthaler and Wuthrich

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.